FDA places hold on Solid's Phase I/II DMD trial

Solid Biosciences Inc. (NASDAQ:SLDB) said FDA placed a clinical hold on the Phase I/II IGNITE DMD trial of Duchenne muscular dystrophy candidate SGT-001 after the first patient treated with the gene therapy was hospitalized. The

Read the full 353 word article

User Sign In